Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 25, 2020
Daily News
November 25, 2020
- Drug Price Negotiations in 1st Half Delayed by COVID-19 Impact: JPWA Survey
November 25, 2020
- Single Product, Single Price Trade Ratio in H1 FY2020 Virtually Flat: MHLW
November 25, 2020
- Ryukaikon Confab Held after 17 Month Hiatus, COVID-19 Impact on Drug Distribution Discussed
November 25, 2020
- MHLW to Issue COVID-19 Immunity Certificate: Parliamentary Secretary
November 25, 2020
- MHLW to Prepare 7,500 More Freezers for COVID-19 Vaccine Storage at Medical Institutions
November 25, 2020
- MHLW Weighing Fixed Brand Vaccine Allocation for Each Medical Institution: Official
November 25, 2020
- COVID-19 Vaccine Distribution Will Be Undertaken by Wholesalers with Certain Track Records: Minister
November 25, 2020
- Takeda to Take Full Control of Nihon Pharm as Plasma Biz Grows
November 25, 2020
- Chugai’s Multigene Panel Test Difficult to Use as CDx, Reimbursement Rules Should Be Revised: KOL
November 25, 2020
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…